BiotechTube

Galunisertib + Lomustine + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioblastoma

Conditions

Glioblastoma

Trial Timeline

Apr 26, 2012 → Oct 10, 2024

NCT ID
NCT01582269

About Galunisertib + Lomustine + Placebo

Galunisertib + Lomustine + Placebo is a phase 2 stage product being developed by Eli Lilly for Glioblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01582269. Target conditions include Glioblastoma.

What happened to similar drugs?

1 of 18 similar drugs in Glioblastoma were approved

Approved (1) Terminated (1) Active (16)
✅TemozolomideMerckApproved
🔄enzastaurin + lomustineEli LillyPhase 3
🔄DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
🔄Temozolomide + Depatuxizumab mafodotin + Placebo for ABT-414AbbViePhase 3
❌Steroid eye drops + Vasoconstrictor eye drops + Ophthalmic steroid ointment + Depatuxizumab mafodotin + TemozolomideAbbViePhase 3
🔄Cediranib + Cediranib + Lomustine Chemotherapy + Placebo CediranibAstraZenecaPhase 3
🔄Cilengitide + TemozolomideMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01582269Phase 2Completed

Competing Products

20 competing products in Glioblastoma

See all competitors
ProductCompanyStageHype Score
TemferonGenenta SciencePhase 1/2
26
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
PLX3397Daiichi SankyoPhase 2
27
ASP8374 + cemiplimabAstellas PharmaPhase 1
29
Nimotuzumab + TemozolomideSun PharmaceuticalPhase 2
35
Gliadel + Avastin + TemodarEisaiPhase 2
27
BCNU Wafer + Irinotecan + BevacizumabEisaiPhase 1/2
24
KHK2455Kyowa KirinPre-clinical
26
olaratumab + ramucirumabEli LillyPhase 2
35
enzastaurin + temozolomideEli LillyPhase 1/2
32
enzastaurin + bevacizumab + Enzyme-inducing antiepileptic drugs (EIAED) + Non-enzyme inducing antiepileptic drugs (NEIAED)Eli LillyPhase 2
35
Temozolomide + Neratinib + QBS10072S + Abemaciclib + CC-115Eli LillyPhase 2
42
AbemaciclibEli LillyPhase 2
39
Enzastaurin 500 milligram (mg) Once Daily (QD) + Enzastaurin 250 mg Twice Daily (BID)Eli LillyPhase 2
35
Abemaciclib + LY3214996Eli LillyPhase 1
29
enzastaurin + lomustineEli LillyPhase 3
40
DSP-7888 Dosing Emulsion + BevacizumabSumitomo PharmaPhase 3
40
DSP-7888Sumitomo PharmaPhase 1/2
32
BBI608 + TemozolomideSumitomo PharmaPhase 1/2
32
Indoximod + Temozolomide + Cyclophosphamide + Etoposide + LomustineJohnson & JohnsonPhase 2
39